fashion -WSS

fashion

author：hotspot 2025-08-19 20:45:19 - browse：685

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Results on Novartis prostate cancer therapy could expand its use

Wikipedia

knowledge

WSS

Coloradans with cystic fibrosis could lose access to Trikafta

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

STAT Summit: How researchers deal with rejection

STAT Summit: Ending the crisis of Black deaths in the U.S.

Life sciences investors close nearly $6 billion in new funds

J&J lung cancer data amount to new salvo against AstraZeneca

leisure time

fashion

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth, Optum discontinue NaviHealth name

At least 13 dead in Texas as scorching temps continue

Kidney transplant patients stopped immunosuppressants in trial

23andMe had bad news about my health. I wish a person had delivered it

Coloradans with cystic fibrosis could lose access to Trikafta

Wildfire smoke exposes gaps in outdoor worker protections

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Novavax promises a turnaround & Lilly roils the obesity market

Cassava Sciences’ Alzheimer’s clinical trials should be halted

hotspot

How neuroscience research could help beat back brain cancer

Live blog: Hearing on CRISPR

Results on Novartis prostate cancer therapy could expand its use

All of Us, NIH's precision medicine initiative, gets a big boost

Study on Amgen’s bispecific immunotherapy produces positive data

Coloradans with cystic fibrosis could lose access to Trikafta

Wikipedia

leisure time

knowledge

hotspot